

An abstract geometric composition on a dark navy blue background. On the left, a vertical cream-colored rectangle is divided by a thin teal line, with two horizontal teal lines intersecting it at points marked by small teal dots. To the right of this, a large teal shape is composed of several geometric parts: a trapezoid at the bottom, a rectangle to its right, and a trapezoid above the rectangle. A thin white vertical line runs from the top of the bottom trapezoid to a small teal circle at the junction of the rectangle and the upper trapezoid. The word "Poland" is written in a white, sans-serif font, centered horizontally in the upper half of the image.

Poland

Poland

Understanding the applicable framework

The INFARMA Code effective from 1 September 2026 addresses patient relationships and disclosure. Earlier editions remain available, so identify the version for new work and historical periods (INFARMA, 2026).

Confirm signatory applicability and distinguish Code, legislation and company procedures. Check statutes, authority and funding conditions before commitments.

What companies need to understand

The Patient Rights Ombudsman's public list covers eligible registered associations and foundations with patient-related purposes. Entry is application-based and distinct from underlying legal registration (Patient Rights Ombudsman, n.d.).

Check identity, purposes and representation. Explain why any list entry is relevant, and assess delivery capacity separately from formal status.

What patient organisations need to understand

Article 29 requires independence, acknowledgement and written or documentary support arrangements. It restricts commercially favourable influence over sponsored materials while allowing substantive error correction and specified balanced cooperation (INFARMA, 2026, art. 29).

Agree company input before drafting. Distinguish factual corrections, requirements and preferences, and identify final editorial responsibility.

Funding and disclosure

The Code addresses public reporting and proof that support was used as agreed (INFARMA, 2026, arts. 29, 32). Agree proportionate records, formats and deadlines before acceptance, with a clear explanation for additional requests.

Confirm legal names, relationship descriptions and correction arrangements. Check old templates against the revised Code.

Regulatory and access participation

AOTMiT supplies assessments, opinions and recommendations; it does not make the final funding decision (Polish Ministry of Health, 2026). Identify the procedure, available input and deadline directly. Do not infer rights in one process from another, and keep official contributions separate from company work.

Practical example and local checks

For supported education and member-experience collection, decide whether the organisation retains responses or the provider receives them. Agree consultation, privacy, editorial control and accounting. Use the current Code for new work and preserve methods, funding and independent findings for any later official submission.